「me」の検索結果
163件：151～155件目を表示
-
B2302 B2302 52 6 mg 2.7% 10/368 1.1% 4/368 RTH258D2301 D2301 96 3 6 mg 5.5% 19/347 PRP 1.2% 4/342 1 MedDRA/J ver. 20.1 4 2 MedDRA/J ver. 23.1 3 MedDRA/J ver. 27.0 1. 2. Endophthalmitis 5 3 mg C001 C00...
https://www.senju.co.jp/system/files/rmp_document/2026-07/BEO_202607_03_RMP.pdf -
テム（ｓｔｅｍ） 該当しない 3．構造式又は示性式 4．分子式及び分子量 分子式：C16H24N2O3・HCl 分子量：328.83 5．化学名（命名法）又は本質 5-[(2RS)-3-(1,1-Dimethylethyl)amino-2-hydroxypropyloxy]-3,4-dihydroquinolin-2(1H)-one monohydrochloride（IUPAC） 6．慣用名、別...
https://www.senju.co.jp/system/files/2021-07/20210705_MK_IF_0.pdf -
产品开发方针 | 研究与开发 | 千寿制药株式会社
#5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analysis of corneal endothelial cells derived from patients with Fuchs endothelial corneal dystro...
http://www.senju.co.jp/chinese/rd/policy/ -
General Announcement: February 20, 2025 Senju Pharmaceutical Co., Ltd. Launch and Distribution of “MIEr for BeelineMED” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distr...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220.pdf -
CEO Message | About Senju | SENJU Pharmaceutical
ju was established in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&D capa...
http://www.senju.co.jp/english/about/message.html